Trial
NCT05169489
A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Regeneron Pharmaceuticals
Collaborators
—
Condition
Diffuse Large B Cell Lymphoma (DLBCL)
Intervention
bbT369
Why stopped
Sponsor Decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-21